-

Endologix to Present in Two Upcoming Healthcare Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the company will be presenting in two upcoming healthcare conferences:

  • The 2023 Stifel Healthcare Conference
    Wednesday, November 15, 2023, at 10:55 AM Eastern Time.

  • Canaccord Genuity Medical Technology and Diagnostics Forum
    Thursday, November 16, 2023, at 9:30 AM Eastern Time.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

Industry:

Endologix LLC

Release Versions
English

Contacts

Sandy Prietto
949-595-7240
sprietto@endologix.com

More News From Endologix LLC

Endologix Acquires Pounce™ Thrombectomy System, Expanding Its Vascular Intervention Portfolio

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™ Thrombectomy System from Surmodics, Inc. The transaction closed on May 18, 2026. The Pounce System is an FDA-cleared, fully mechanical thrombectomy system for the non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary...

Endologix Announces Appointment of Steve Deitsch to Board of Directors

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the appointment of Steve Deitsch to its Board of Directors. Mr. Deitsch brings more than 25 years of global leadership experience across medtech and the broader healthcare sector. He currently serves as Chief Executive Officer of Caristo Diagnostics, a global leader in AI technology for...

Endologix Announces that Scott Huennekens Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that R. Scott Huennekens has been appointed to the Endologix Board of Directors. Mr. Huennekens is a highly regarded medtech CEO, chairperson, entrepreneur and investor, serving an impressive list of companies. Previously, he led Volcano Corp. (VOLC), a leader in minimally invasive...
Back to Newsroom